---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Pathophysiology"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Pathophysiology. Topics: Pathophysiology, Bradykinin generation: activation of prekallikrein to plasma kallikrein, Role of C1 inhibitor in regulating the kallikrein-kinin system, Bradykinin and vascular permeability, and 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/pathophysiology"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Pathophysiology

> “Hereditary angioedema (HAE) is characterized by C1 esterase inhibitor (C1INH) deficiency, leading to uninhibited kallikrein-kinin system (KKS) activation and bradykinin production resulting in angioedema attacks”

Source: [Intellia Therapeutics AAAAI poster (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_KKS-Modeling-Poster_with-Supplement.pdf)

<a id="topic-2.2.1.4-2"></a>

### Bradykinin generation: activation of prekallikrein to plasma kallikrein

> “In HAE-C1-INH, bradykinin is the primary mediator of swelling.”
> “This molecule arises from cleavage of high-molecular-weight kininogen by plasma kallikrein, which is activated from prekallikrein by factor XII.”
> “The resulting bradykinin nonapeptide increases vascular permeability and induces swelling (angioedema) through a specific receptor, B2”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-3"></a>

### Role of C1 inhibitor in regulating the kallikrein-kinin system

> “C1-INH is a serine protease inhibitor protein synthesized in hepatocytes that is crucial in regulating the plasma kallikrein–kinin system (KKS) and preventing excessive bradykinin production.”
> “HAE-C1-INH is caused by mutations in SERPING1, which encodes C1-INH, leading to reduced levels or impaired activity of C1-INH.”
> “This deficiency in turn leads to uncontrolled activation of the KKS and excessive bradykinin production, with bradykinin acting as the key mediator of the condition.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-4"></a>

### Bradykinin and vascular permeability

> “When the body does not have enough normal C1-INH protein, it ends up with excessive amounts of a protein fragment (peptide) called bradykinin.”
> “Bradykinin promotes inflammation by increasing the amount of fluid that leaks through the walls of blood vessels into body tissues (vascular permeability).”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.4-5"></a>

### Plasma prekallikrein as the target of onvuzosiran

> “Hereditary angioedema (HAE) is a rare genetic disorder caused by dysregulation of the plasma kallikrein pathway, leading to recurrent, unpredictable attacks of swelling that can be painful, disabling, and life-threatening.”
> “ADX-324 is an investigational siRNA therapy designed to inhibit prekallikrein (PKK) generation at the mRNA level and reduce the production of plasma PKK, thereby averting bradykinin generation and potentially preventing HAE attacks.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
